CG
SIOX

Cutler Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Cutler Group’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,000
Closed -$2K – 6533
2020
Q4 		$2K Buy
+2,000
New +$5.82K ﹤0.01% 4307
2020
Q1 		– Sell
-7,500
Closed -$14K – 4871
2019
Q4 		$14K Buy
+7,500
New +$41.6K ﹤0.01% 2462
2018
Q3 		– Sell
-900
Closed -$6K – 4893
2018
Q2 		$6K Buy
+900
New +$13.3K ﹤0.01% 3042
2018
Q1 		– Sell
-75
Closed -$1K – 5483
2017
Q4 		$1K Sell
75
-15,650
-100% -$702K ﹤0.01% 4662
2017
Q3 		$474K Buy
15,725
+13,900
+762% +$2.34M 0.02% 689
2017
Q2 		$52K Buy
1,825
+862
+90% +$151K ﹤0.01% 2467
2017
Q1 		$19K Buy
963
+875
+994% +$91.7K ﹤0.01% 3403
2016
Q4 		$2K Sell
88
-212
-71% -$22.3K ﹤0.01% 5758
2016
Q3 		$1K Sell
300
-350
-54% -$42K ﹤0.01% 6386
2016
Q2 		$3K Sell
650
-7,975
-92% -$797K ﹤0.01% 5473
2016
Q1 		$135K Buy
+8,625
New +$920K 0.01% 1334

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $195M AUM 29.88% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Cutler Group's SIOX Position: Q1 2021 in Review

Cutler Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2021, closing a stake of 2,000 shares — an estimated $5K sold.

Cutler Group first reported a position in SIOX in Q4 2015 and held it in 16 quarters. The position peaked at $510K in Q2 2017. 56 funds tracked by Wall St. Rank hold SIOX as of Q1 2021.

  • Cutler Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Cutler Group sold 2,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2021, an estimated $5K.
  • Cutler Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2015 and held it in 16 quarters.
  • Cutler Group's Sio Gene Therapies Inc. Common Stock position peaked at $510K in Q2 2017.
  • 56 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2021.

Based on Cutler Group's 13F filing for Q1 2021, filed 26 Apr 2021.